Great question - but a total wild card. I personally don't expect it, unless the shortage of morphine continues to rise over the next few months. There would need to be an event that would trigger the use of more pain medications... hate to say it. That would give the FDA an added "push" to review and potentially approve, based on the efficacy and safety data that exists today.
The coronavirus pandemic that is making its way across most countries (albeit statistics are still debatable due to lack of data and evidence), most likely helps elevate the BIO market, but does it have a direct correlation to morphine and/or pain administration? I can't officially say. I'm no doctor, nor do I know the "official protocol" for treating the illness, but mostly is upper respiratory w/ some theaters saying it can lead to viral encephalitis. Whether morphine is administered in these cases or not, I'd leave that up to a medical professional to comment on. My belief is that it is not used in these cases, unless severe pain were present that would require such a dosage.
Hope that helps... just an FYI, I'm long TRVN w/ over 100K shares.
News 
Market Data 
Discover 
